[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343604-105":59,"doc-detail-343604-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumour-intrinsic-pdl1-signals-regulate-the-chk2-dna-damage-response-in-cancer-cells-and-mediate-resistance-to-chk1-inhibitors-abstract","Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors - Abstract","","Aside from the canonical role of PDL1 as a tumour surface immune checkpoint, tumour-intrinsic PDL1 signals drive non-canonical immunopathological pathways that mediate treatment resistance, with key mechanisms still unclear. This work examines how tumour-intrinsic PDL1 shapes the DNA damage response, using genetic depletion in mouse and human cancer models, complementary primary tumour studies, and pharmacologic in vivo depletion with repurposed FDA-approved drugs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumour-intrinsic-pdl1-signals-regulate-the-chk2-dna-damage-response-in-cancer-cells-and-mediate-resistance-to-chk1-inhibitors-abstract/343604/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumour-intrinsic-pdl1-signals-regulate-the-chk2-dna-damage-response-in-cancer-cells-and-mediate-resistance-to-chk1-inhibitors-abstract/343604.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does tumour-intrinsic PDL1 influence the DNA damage response?","Question",{"text":112,"@type":113},"Tumour-intrinsic PDL1 promotes the Chk2-mediated DNA damage response, shaping checkpoint kinase activity and downstream repair signaling in cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the mechanistic relationship between intracellular PDL1 and Chk2 stability?",{"text":117,"@type":113},"Intracellular PDL1 controls Chk2 protein content post-translationally by antagonising PIRH2 E3 ligase–mediated Chk2 polyubiquitination and degradation.",{"name":119,"@type":110,"acceptedAnswer":120},"How does tumour PDL1 depletion affect sensitivity to Chk1 inhibitors?",{"text":121,"@type":113},"Genetic or pharmacologic depletion of tumour PDL1 reduces tumour Chk2, triggers Chk1 inhibitor synthetic lethality in vitro, improves Chk1 inhibitor efficacy in vivo, and reduces tumour growth when combined with Chk1 inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343604,1790193220,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Murray et al. Molecular Cancer (2024) 23:242 [https://doi.org/10.1186/s12943-024-02147-z](https://doi.org/10.1186/s12943-024-02147-z)  \nMolecular Cancer  \n RESEARCH Open Access  \nTumour-intrinsic PDL1  \nsignals regulate  \nthe Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors  \nClare E. Murray 1†, Anand V. R. Kornepati 1,17†, Carlos Ontiveros1, Yiji Liao2, Bárbara de la Peña Avalos3,  \nCody M. Rogers3, Zexuan Liu4, Yilun Deng4, Haiyan Bai2, Suresh Kari4, Alvaro S. Padron4, Jacob T. Boyd 1, Ryan Reyes1, Curtis A. Clark 1,18, Robert S. Svatek5,6, Rong Li7,19, Yanfen Hu7,20, Meiling Wang3,  \nJosé R. Conejo-Garcia9, Lauren A. Byers 10, Kavya Ramkumar10, Anil K. Sood 11, Jung-Min Lee 12,  \nChristin E. Burd 13 , Ratna K. Vadlamudi4,6, Harshita B. Gupta3, Weixing Zhao3, Eloïse Dray3, Patrick Sung3,6 and Tyler J. Curiel 1,2,4,8,14,15,16,21*  \nAbstract  \nBackground Aside from the canonical role of PDL1 as a tumour surface-expressed immune checkpoint molecule, tumour-intrinsic PDL1 signals regulate non-canonical immunopathological pathways mediating treatment resistance whose significance, mechanisms, and therapeutic targeting remain incompletely understood. Recent reports implicate tumour-intrinsic PDL1 signals in the DNA damage response (DDR), including promoting homologous recombination DNA damage repair and mRNA stability of DDR proteins, but many mechanistic details remain undefined. Methods We genetically depleted PDL1 from transplantable mouse and human cancer cell lines to understand consequences of tumour-intrinsic PDL1 signals in the DNA damage response. We complemented this work with studies of primary human tumours and inducible mouse tumours. We developed novel approaches to show tumour-intrinsic PDL1 signals in specific subcellular locations. We pharmacologically depleted tumour PDL1 in vivo in mouse models with repurposed FDA-approved drugs for proof-of-concept clinical translation studies.  \nResults We show that tumour-intrinsic PDL1 promotes the checkpoint kinase-2 (Chk2)-mediated DNA damage response. Intracellular but not surface-expressed PDL1 controlled Chk2 protein content post-translationally and independently of PD1 by antagonising PIRH2 E3 ligase-mediated Chk2 polyubiquitination and protein degradation. Genetic tumour PDL1 depletion specifically reduced tumour Chk2 content but not ATM, ATR, or Chk1 DDR proteins, enhanced Chk1 inhibitor (Chk1i) synthetic lethality in vitro in diverse human and murine tumour models, and improved Chk1i efficacy in vivo. Pharmacologic tumour PDL1 depletion with cefepime or ceftazidime replicated genetic tumour PDL1 depletion by reducing tumour Chk2, inducing Chk1i synthetic lethality in a tumour PDL1-dependent manner, and reducing in vivo tumour growth when combined with Chk1i.  \n†Clare E. Murray and Anand V. R. Kornepati contributed equally to this work.  \n*Correspondence:  \nTyler J. Curiel  \n[tyler.j.curiel@dartmouth.edu](tyler.j.curiel@dartmouth.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyr","cbCaisgDEq48NTji","https://ap.wps.com/l/cbCaisgDEq48NTji","pdf",6337405,24,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background (Introduction)\n## Canonical PDL1 signaling and immunotherapy response\n## Tumour-intrinsic PDL1 signaling as a resistance program","[{\"question\":\"How does tumour-intrinsic PDL1 influence the DNA damage response?\",\"answer\":\"Tumour-intrinsic PDL1 promotes the Chk2-mediated DNA damage response, shaping checkpoint kinase activity and downstream repair signaling in cancer cells.\"},{\"question\":\"What is the mechanistic relationship between intracellular PDL1 and Chk2 stability?\",\"answer\":\"Intracellular PDL1 controls Chk2 protein content post-translationally by antagonising PIRH2 E3 ligase–mediated Chk2 polyubiquitination and degradation.\"},{\"question\":\"How does tumour PDL1 depletion affect sensitivity to Chk1 inhibitors?\",\"answer\":\"Genetic or pharmacologic depletion of tumour PDL1 reduces tumour Chk2, triggers Chk1 inhibitor synthetic lethality in vitro, improves Chk1 inhibitor efficacy in vivo, and reduces tumour growth when combined with Chk1 inhibitors.\"}]","Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors - Abstract | PDF",1790051551,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/055aaad44ed29e27081fe2ccaa402d62.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95267e3d638a4d617ef17befd32f1848.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de730f223d2d386eb759dfea09bd030f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fd2c2ba29e15557cea4880b31772c270.webp",980,1301]